Amyotrophic lateral sclerosis (ALS) is a rare neurological disorder. Market Research Future (MRFR) has published a research
report about the global amyotrophic lateral sclerosis market that forecasts
boost for this market at 7.89% CAGR (Compound Annual Growth Rate) between 2018
and 2023. By value, the market is expected to be worth US $ 841.6 mn by the end
of forecast period.
Get Free sample @ https://www.marketresearchfuture.com/sample_request/5822
The key factors driving
the global amyotrophic
lateral sclerosis market include an increase in the incidence rate of ALS, the
rise in the awareness about the disease
among patients, inclination towards the sedentary lifestyle, rise in the
geriatric population, and demand for symptomatic as well as targeted treatment
options. However, the high cost of the treatment of ALS can slow down the
market growth.
The global amyotrophic
lateral sclerosis market has been segmented on the basis
of end user, type, treatment, and lastly, region. Based on end users, this market
has been segmented into hospitals, research & academic institutes,
specialty centers, and others. During the
forecast period, the hospital is expected to witness the highest growth.
By type, the market has been segmented
into familial ALS and sporadic ALS. During the forecast period, sporadic ALS is
expected to dominate the market. The treatment-based
segmentation segments this market into medication, physical therapy,
respiratory therapy, speech therapy, and others.
The regional segmentation
of the global amyotrophic lateral sclerosis market segments the global market
into regional markets known as The Americas (North America & South
America), Europe, Asia Pacific, and the Middle East & Africa (MEA).
The Americas hold the largest market share of
the global market as North America alone is capable of holding this
share anyways. Due to technology, North America is a bigger market than South
America. In North America (and some parts of
South America), the market is growing due government support for
research & development (R&D), increasing the pool of awareness, availability of advanced medical facilities, the
rising prevalence of hypertension, and presence of many key market players. In
North America, the most powerful economies that can be important
country-specific markets are USA and Canada. In North America, especially in the
USA, public and private organizations are
involved in collaborations and strategic partnerships in search for a better
outcome in the research of amyotrophic lateral sclerosis treatment. In South
America, Argentina and Brazil are two strong economies that can be suitable
markets in the future.
Europe is the second largest regional
market mainly due to the well-established healthcare sector. Several companies
and research institutes are establishing advanced facilities to research ALS.
In Europe, due to reasons same as The Americas, Western Europe is a bigger
market than Eastern Europe. The most powerful economies that can be suitable
markets in this region are France, Germany, and the UK.
During the forecast
period, the Asia Pacific region is expected to
grow rapidly as a regional market. Important factors leading to market growth
include the increasing prevalence of the ailment and rapidly developing
healthcare infrastructure. Other factors contributing to the market growth
include the presence of growing economies like China and India. The increase in
the setups of research and development (R&D) centers also aiding the market
growth. Other important country-specific markets
in this region are Australia, Japan, and South Korea, followed by the
remaining countries of the Asia Pacific
region.
The MEA region holds the
smallest market share in the global market. In this region, the market is small
and limited due to poor countries, lack of awareness, lack of advanced medical
facilities, low standard of medical facilities, lack of education, lack of
healthcare facilities, and most governments not considering healthcare a
priority.
Key Players
The key players in the
global amyotrophic lateral sclerosis market include Apotex Inc. (Canada),
Ascend Pharmaceuticals LLC (USA), Biogen (USA), Covis Pharma (Switzerland),
Ionis Pharmaceutical (USA), ITF Pharma (USA), Mitsubishi Tanabe Pharma America
(USA), Mylan N.V. (USA), Sanofi (France), and Sun Pharmaceutical (India).
Latest
Industry News
·
The US Food and Drug
Administration (FDA) has granted Fast Track designation to Revalesio’s
experimental therapy RNS60 for people diagnosed with ALS. A phase 2 trial has now started recruiting participants. 7 JAN 2019
·
According to a new study,
the human-derived antibody that can specifically bind to abnormal superoxide
dismutase 1 (SOD1) has improved the symptoms and delayed disease progression in
a mouse model for ALS. 14 JAN 2019
Read More @ https://www.marketresearchfuture.com/reports/amyotrophic-lateral-sclerosis-market-5822
About Market Research Future:
Market Research Future (MRFR) is a global
market research company that takes pride in its services, offering a complete
and accurate analysis with regard to diverse markets and consumers worldwide.
Market Research Future has the distinguished objective of providing the optimal
quality research and granular research to clients. Our market research studies
by products, services, technologies, applications, end users, and market
players for global, regional, and country level market segments, enable our
clients to see more, know more, and do more, which help answer your most
important questions.
Contact:
Market Research Future
Phone:
+1 628 258 0071(US)
+44 2035 002 764(UK)
No comments:
Post a Comment